IP Verse

Apixaban Formulations

PatentPatent Analysis

EP3017811

BRISTOL MYERS SQUIBB
Application Number
EP15190823A
Filing Date
Feb 24, 2011
Status
Revoked
Mar 22, 2024
Grant Date
Dec 5, 2018
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3781132B1
EP3818078B1
EP3631454B1

Biblio Summary

The patent EP3017811B1 was granted to Bristol Myers Squibb on Dec 5, 2018 following the initial filing on Feb 24, 2011 under the application number EP15190823A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

STADA ARZNEIMITTELSep 5, 2019ADMISSIBLE
GENERICS UKSep 4, 2019ADMISSIBLE
ZENTIVASep 4, 2019ADMISSIBLE
INTAS PHARMACEUTICALSSep 4, 2019WITHDRAWN
POLPHARMASep 3, 2019ADMISSIBLE
KRKASep 3, 2019WITHDRAWN
HAMM & WITTKOPPAug 30, 2019ADMISSIBLE
SANDOZAug 29, 2019ADMISSIBLE
TEVA PHARMACEUTICALSAug 27, 2019ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents